CA-THEOREMONE
25.1.2022 00:39:08 CET | Business Wire | Press release
Theorem, LLC, innovation and engineering partner to the Global 1000, today announced that it has rebranded to TheoremOne® following an acquisition of Formula Partners , and launch of its near-shore, pureplay software engineering service, Lemma . The new name positions TheoremOne as the foundation of a family of brands designed to help enterprises build better, more innovative business platforms at scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220124005847/en/
“Our new name positions TheoremOne as the foundation of a family of brands, all inspired by our hypothesis driven model for innovation. Each brand is designed to address the specific needs of our clients at different moments in the lifecycle of enterprise innovation,” said Brady Brim-DeForest, CEO of TheoremOne.
Its newest acquisition, Formula Partners, helps companies create new models for organizational design, continuous improvement, and visionary leadership. Formula Partner’s approach revolves around a modular innovation process called the New Enterprise™, a proprietary model for modern consulting at the nexus of technology and organizational transformation. Formula Partners will become a new independent line of business and will operate under the “Formula Partners” brand.
“We are approaching management consulting from 14 years of implementing technology solutions — giving us a deep understanding of the true benefits (and costs) of making strategic recommendations. We’ve built trust with IT and business leaders through hands-on work, and we’re excited to build even broader strategic relationships through Formula Partners,” said Will Jessup, Head of Services Delivery at TheoremOne.
TheoremOne has also launched a new engineering service called Lemma. Lemma offers pureplay software engineering teams staffed exclusively by nearshore engineering talent. Lemma shares a common engineering DNA with TheoremOne but is designed to deliver engineering capacity as a modular service offering that can be deployed to scale existing teams and initiatives for enterprise and growth stage clients.
“Lemma fills a gap in our offerings that the market has illuminated over the last few years,” said Alex Finnemore, TheoremOne’s Head of Revenue. “It’s a compelling option for clients that have already determined the right way to solve a business problem and need a dedicated technology partner, but want to provide their own product, design, and leadership talent.”
Lemma and Formula Partners will join existing divisions Proof (staff augmentation) and Halmos Ventures (innovation incubation) in rounding out TheoremOne’s end-to-end services stack.
As part of the name change, TheoremOne has released a new company logo and launched a new website at www.theoremone.co .
About TheoremOne®
TheoremOne is an innovation and engineering firm that builds custom software for companies making bold bets to stay ahead. Through research, lean design, and agile delivery, TheoremOne makes great user experiences accessible to the enterprise. Founded in 2007, TheoremOne’s global cross-functional product development teams drive technology, process, and cultural transformation. To learn more about how TheoremOne enables ambitious leaders to build better software visit www.theoremone.co or follow @TheoremOne
About Formula Partners
Formula Partners is a different kind of management consulting firm — it targets the intersection of technology and organizational transformation, unlocking models for continuous improvement, and enabling visionary leadership within the enterprise. Founded in 2015, Formula Partners is based in Los Angeles. Read more at: www.formula.partners .
About Lemma
Lemma offers pureplay software engineering teams designed to deliver high-quality results at-scale. Clients come to Lemma when they need an injection of fully-managed and modular engineering talent. Learn more about Lemma at: www.thinklemma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220124005847/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom